Ozagrel

Chemical name

(E)-3-[4-(1Н-Имидазол-1-илм��тил)фенил]-2-пропеноев ая acid

Gross

C13-H12-N2-O2

Of drugs

The drugs-protiwallergicescoe, antiagregatine, antitromboticescoe. Ingibiruet ziklooksigenzu and tromboksan A_2-sintetazu. Impact synthesis tromboksana A_2, inducyrovannuu arahidonova acid agregatia platelets, prolongs bleeding time. Decreases of allergen in the respiratory passages (swelling of mucous membranes bronhospazm).

Indications

Bronchial asthma (atopica light running); Trombozov prevention.

Restrictions on the use of

Hematology diseases and syndromes, accompanied by high krovotochivostyu, pregnancy, breast-feeding (at the time of treatment are encouraged to stop breast-feeding).

Contraindications

Hypersensitivity, the children's age.

Side-Effects

Nausea, vomiting, stomachache, constipation, headache, tachycardia, bleeding, pain in the joints, skin allergic reactions.

Patient interaction

Do antiagregazionny tiklopidina effect, increases the risk of bleeding in the treatment and fibrinolitikami antikoagulyantami.

Precautions

Is not recommended for cupping the asthma.

Dosing and Administration

Inside, in the 100-200 mg twice a day (after breakfast and before bedtime).

Literature

1. Terashita Z., Y. Imura, M. Kawamura et al. Effects of thromboxane A2 synthase inhibitors (CV-4151 and ozagrel), aspirin, and ticlopidine on the thrombosis caused by endothelial cell injury / / Thrombosis Res-1995 .- V. ff9 77-N-5 P. 411-421.

Directory → Интермедианты → Prostaglandins, tromboksana, lakotriena and their antagonists → Ozagrel